Mycophenolic acid

Research use only, not for human use.

Mycophenolic acid is an an immunosuppresant drug and has potent anti-proliferative activity.

Mycophenolic acid is an an immunosuppresant drug and has potent anti-proliferative activity.

Cell Proliferation Assay Cell Line:Primary isolated human dermal microvascular endothelial cells (HDMVEC)?, fibroblasts, U87 glioblastoma cells, PC3 prostate cancer cells,A549 non-small cell lung cancer cells Concentration:0.01, 0.1, 1 μM Incubation Time:72 hours Result:Exhibited preferential antiproliferative activity against HDMVEC and fibroblasts. Whereas U87 glioblastoma cells were resistant to treatment, A549 non-small cell lung cancer and PC3 prostate cancer cells showed intermediate sensitivity.?Western Blot AnalysisCell Line:HDMVEC Concentration:0, 0.05, 0.1, 0.5, 1, and 2 μM Incubation Time:18 hours Result:Showed a dose-dependent regulation of HDAC2, MYC, and NDRG1.?

Animal Model:Athymic 8-week-old, 20 g BALB/c?nu/nu?mice bearing Mycophenolic acid-resistant human U87 tumor model Dosage:120 mg/kg MMF (the morpholinoethyl ester prodrug of Mycophenolic acid)Administration:Oral gavage; b.i.d. Result:MMF (the morpholinoethyl ester prodrug of Mycophenolic acid) significantly inhibited tumor growth (～70% after day 14 after tumor implantation) in MMF-treated versus control mice.Microvessel density (CD31 staining) and pericyte coverage determined by α-smooth muscle actin staining were markedly reduced in MMF-treated versus control tumors (44% and 78%, respectively).

MPA | NSC 129185

Metabolic Enzyme/Protease

Dehydrogenase

DH| UGT

Inflammation/Immunology

——

24280-93-1

320.34

C17H20O6

>98% (HPLC)

Ethanol: 5 mg/mL (15.6 mM); DMSO: 64 mg/mL (199.78 mM)

O=C(OCCN1CCOCC1)CC/C(C)=C/CC2=C(OC)C(C)=C(C3=C2O)COC3=O

2-morpholin-4-ylethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1H-2-benzofuran-5-yl)-4-methylhex-4-enoate

(-20℃)

With Ice Pack

≥ 2 years